Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

6d ago, source:

Lyell Immunopharma's stock price rose over 20% YTD. It focuses on T-cell therapies for solid tumors and has 2 clinical-stage ...

LYEL Lyell Immunopharma, Inc.

3d ago, source: Seeking Alpha

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic ...

Lyell Immunopharma Inc (LYEL) Shares Rise Despite Market Challenges

13d ago, source: newsheater

The stock of Lyell Immunopharma Inc (NASDAQ: LYEL) has increased by 14.98 when compared to last closing price of 2.19. Despite this, the company has experienced a 21.06% gain in its stock price over ...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

1mon ago, source: Stockhouse

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies ...

Lyell Immunopharma, Inc. (LYEL) stock forecast and price target

3mon ago, source: Yahoo Finance

Find the latest Lyell Immunopharma, Inc. LYEL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Lyell Immunopharma Inc Ordinary Shares LYEL

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Lyell Immunopharma Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lyell Immunopharma Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Lyell Immunopharma Inc (LYEL)

5d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Lyell Immunopharma Inc.

1mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...